Salvage radiation given over 26 sessions kept prostate cancer in check as well as the conventional schedule did, according to ...

Use of active surveillance for early prostate cancer increased sharply in the VA healthcare system over the past couple ...

Investigators characterized active surveillance use for favorable intermediate-risk prostate cancer in the US Veterans Affairs System.

John Douglas, a Long Island physical therapist, was diagnosed with metastatic prostate cancer after pushing for a more ...

A research letter published in JAMA has revealed a shift toward active surveillance for favorable-risk prostate cancer within ...

When prostate cancer spreads to distant parts of the body, doctors need fast and reliable ways to judge whether treatment is ...

Doctors often use a blood test called prostate-specific antigen, or PSA, to follow prostate cancer. When treatment works, PSA ...

Investigators evaluated real-world results to assess the association between PSA response and overall survival in patients with metastatic castration‐sensitive prostate cancer.

In the past decade, an increasing number of approved therapies with various mechanisms of action have become available for metastatic castration-resistant prostate cancer (mCRPC), but the associated ...

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working.

A real-world analysis suggests that achieving a prostate-specific antigen (PSA) level < 0.2 ng/mL within 9 months of starting androgen deprivation therapy (ADT)-based treatments was the PSA benchmark ...

A 9-month PSA <0.2 ng/mL after ADT initiation was associated with substantially better overall survival (adjusted HR 0.46) and lower progression risk versus not achieving it. Depth-to-threshold ...